微循环学杂志
微循環學雜誌
미순배학잡지
CHINESE JOURNAL OF MICROCIRCULATION
2015年
3期
34-37
,共4页
易蕾%雷蕾%杜丹心%张明洁
易蕾%雷蕾%杜丹心%張明潔
역뢰%뢰뢰%두단심%장명길
椎-基底动脉供血不足%灯盏细辛%倍他司汀%内皮素-1%血管性血友病因子%一氧化氮
椎-基底動脈供血不足%燈盞細辛%倍他司汀%內皮素-1%血管性血友病因子%一氧化氮
추-기저동맥공혈불족%등잔세신%배타사정%내피소-1%혈관성혈우병인자%일양화담
Vertebral-basilar artery insufficiency%Erigeron Breviscapus%Betahistine%Endothelin-1%Von Willebrand factor%Nitrogen monoxide
目的：：回顾性分析灯盏细辛+倍他司汀治疗椎-基底动脉供血不足(VBI)的临床疗效及对患者血管内皮功能指标血浆内皮素-1(ET-1)、血管性血友病因子(vWF)和血清一氧化氮(NO)水平的影响。方法：140例临床确诊 VBI 患者,按随机数字表法分为治疗对照组(n=70,采用倍他司汀片治疗)和联合治疗组(n=70,采用灯盏细辛注射液+倍他司汀片治疗)。治疗14天后,观察比较两组临床疗效以及 ET-1、vWF 和 NO 水平变化和组间差异。结果：联合治疗组显效率及总有效率分别为71.42%和91.43%,明显优于治疗对照组的45.71%和78.57%(P <0.05)；治疗前,与正常对照组比较,两组 VBI 患者 ET-1及 vWF 水平均明显升高,NO 水平显著下降(P <0.05)；治疗后,联合治疗组 ET-1及 vWF 水平较治疗前及治疗对照组治疗后均明显降低(P <0.01),NO 水平均明显升高(P <0.01),且恢复至正常对照组水平(P >0.05)。两组治疗期间均未发生脑及其它脏器出血等药物不良反应。结论：灯盏细辛+倍他司汀能显著改善 VBI 患者血管内皮功能,提高临床疗效。
目的：：迴顧性分析燈盞細辛+倍他司汀治療椎-基底動脈供血不足(VBI)的臨床療效及對患者血管內皮功能指標血漿內皮素-1(ET-1)、血管性血友病因子(vWF)和血清一氧化氮(NO)水平的影響。方法：140例臨床確診 VBI 患者,按隨機數字錶法分為治療對照組(n=70,採用倍他司汀片治療)和聯閤治療組(n=70,採用燈盞細辛註射液+倍他司汀片治療)。治療14天後,觀察比較兩組臨床療效以及 ET-1、vWF 和 NO 水平變化和組間差異。結果：聯閤治療組顯效率及總有效率分彆為71.42%和91.43%,明顯優于治療對照組的45.71%和78.57%(P <0.05)；治療前,與正常對照組比較,兩組 VBI 患者 ET-1及 vWF 水平均明顯升高,NO 水平顯著下降(P <0.05)；治療後,聯閤治療組 ET-1及 vWF 水平較治療前及治療對照組治療後均明顯降低(P <0.01),NO 水平均明顯升高(P <0.01),且恢複至正常對照組水平(P >0.05)。兩組治療期間均未髮生腦及其它髒器齣血等藥物不良反應。結論：燈盞細辛+倍他司汀能顯著改善 VBI 患者血管內皮功能,提高臨床療效。
목적：：회고성분석등잔세신+배타사정치료추-기저동맥공혈불족(VBI)적림상료효급대환자혈관내피공능지표혈장내피소-1(ET-1)、혈관성혈우병인자(vWF)화혈청일양화담(NO)수평적영향。방법：140례림상학진 VBI 환자,안수궤수자표법분위치료대조조(n=70,채용배타사정편치료)화연합치료조(n=70,채용등잔세신주사액+배타사정편치료)。치료14천후,관찰비교량조림상료효이급 ET-1、vWF 화 NO 수평변화화조간차이。결과：연합치료조현효솔급총유효솔분별위71.42%화91.43%,명현우우치료대조조적45.71%화78.57%(P <0.05)；치료전,여정상대조조비교,량조 VBI 환자 ET-1급 vWF 수평균명현승고,NO 수평현저하강(P <0.05)；치료후,연합치료조 ET-1급 vWF 수평교치료전급치료대조조치료후균명현강저(P <0.01),NO 수평균명현승고(P <0.01),차회복지정상대조조수평(P >0.05)。량조치료기간균미발생뇌급기타장기출혈등약물불량반응。결론：등잔세신+배타사정능현저개선 VBI 환자혈관내피공능,제고림상료효。
Objective:To analysis of the therapeutic effect to vertebral-basilar artery insufficiency (VBI)pa-tients by treating with erigeron breviscapus and betahistine,and then observe its impact on the levels of endothelin-1 (ET-1),von willebrand factor (vWF)and nitrogen monoxide (NO).Method:140 cases of clinically diagnosed pa-tients with VBI were divided into control treatment group (n = 70,only treated with betahistine)and combined treatment group (n=70,treated with a combination therapy of erigeron breviscapus and betahistine)according to the random number table.The therapeutic effect after 14-days'treatment and the levels of ET-1,vWF and NO of the 140 patients were detected.Results:After treatment,the significant efficiency and total effective efficiency of the combined treatment group were 71.42% and 91.43% respectively,which were apparently superior to 45.71% and 78.57% of the control treatment group (P <0.05).Before the treatment,compared with the normal control group, patients with VBI had increased levels of ET-1 and vWF and decreased level of NO (P <0.05 ).Then after treat-ment,the levels of ET-1 and vWF of the combined treatment group decreased significantly compared with that be-fore treatment and with that of the control treatment group (P <0.01).The level of NO increased significantly after the combination treatment (P <0.01),and it almost returned back to normal control levels (P >0.05).There was not any bleeding in patients'brains or other organs during the treatments.Conclusion:Erigeron breviscapus combined with betahistine treatment can make significant improvements in VBI patients’vascular endothelial function and en-hance the therapeutic effect.
